entertainment -WSS

entertainment

author：knowledge 2025-10-02 12:32:21 - browse：4

Adobe

The Food and Drug Administration has cleared Otsuka Pharmaceutical’s digital treatment for major depressive disorder, offering a new option for millions of people who struggle with the stubborn mental health condition.

Called Rejoyn, the smartphone-based treatment for major depressive disorder symptoms was developed with digital health company Click Therapeutics, and it is intended for use by prescription alongside antidepressants. The six-week program delivers a novel “cognitive-emotional training” technique, in which people are asked to identify and recall faces showing different emotions. Researchers hypothesize that the technique targets the brain’s dorsolateral prefrontal cortex and the amygdala and may “enhance cognitive control over emotional information processing.” Patients also receive cognitive behavioral therapy.

Rejoyn has been in development since 2018, and Otsuka is the first drug company to receive FDA clearance for a digital treatment for a mental health condition. But that landmark comes amid many questions about whether such digital therapeutics deliver their advertised results — and whether they can gain traction with clinicians, insurers, and patients. Prescription digital therapeutics have yet to see a blockbuster success, and several companies have gone out of business trying to create one.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： What it’s like to watch children die of measles

WSS

Fentanyl is making it harder to start addiction treatment

For longer

What it’s like to watch children die of measles

First medicine developed to treat MASH expected to be approved soon

First medicine developed to treat MASH expected to be approved soon

Cue Health, Covid

explore

entertainment

Wikipedia

Moonlake's readout produced a cash windfall. Risks remain

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

CDC marks new Covid

Medical leaders decry Supreme Court decision on affirmative action

How to bring more disabled researchers into academia

Medical records are filled with copy

Addressing health care workers' trauma can help fight burnout

Peter Hotez and the public health issue of online harassment

Citing H5N1 threat, CDC urges peak flu monitoring this summer

hotspot

Biogen joins immunology wave with $1.15 billion acquisition of HI

First medicine developed to treat MASH expected to be approved soon

Biogen joins immunology wave with $1.15 billion acquisition of HI

FDA poised to publish guidelines for clinical trial diversity

Listen: More tumult at BIO & coercive care for sickle cell patients

IVF, abortion rights issues kick off Biden’s State of the Union

leisure time

focus

focus

Wikipedia